AI-powered data analysis boosts women’s health

This platform analyses existing, unstructured data to deliver actionable insights

Spotted: According to Nature, diseases that affect mainly women pose some of the largest health burdens but often receive the least amount of funding – much less funding, for instance, than conditions that predominantly affect men. AI company Cercle was founded to try and redress this gap.

Cercle is hoping to improve women’s health funding by using AI to transform de-identified healthcare data into real-time, high-quality insights. This data can then be used by women’s healthcare providers to provide more efficient and personalised care and develop drugs faster.

Called the Cercle Biomedical Graph, the company’s platform securely collects biomedical and genomics data from research labs and healthcare clinics around the world, taking in billions of data points. It then converts this unstructured, fragmented clinical data into actionable insights, so that healthcare organisations can offer a better experience to their patients and improve outcomes. The company claims its platform is the first and only one of its kind.

Cercle has already partnered with DNA sequencing services provider, Eurofins Genoma, and US Fertility, one of the largest physician-owned networks of fertility centres, to improve in vitro fertilisation success rates. However, the startup also hopes to transform other areas of women’s healthcare, including reproductive health, menopause, women’s oncology, and other diseases that disproportionately impact women.

The Biomedical Graph is HIPAA- and GDPR-compliant, ensuring the highest degrees of data privacy and security. Cercle recently raised $6 million in a seed funding round led by Outsiders Fund, an early-stage venture capital firm supporting founders who disrupt overlooked, antiquated, and long-standing industries. Additional investments were made by funds and angel investors focused on women’s health.

Written By: Lisa Magloff